| Literature DB >> 29285293 |
Terry Fei Fan Ng1,2,3,4, Jennifer A Dill3, Alvin C Camus3, Eric Delwart1,2, Erwin G Van Meir5.
Abstract
The role of viral infections in the etiology of brain cancer remains uncertain. Prior studies mostly focused on transcriptome or viral DNA integrated in tumor cells. To investigate for the presence of viral particles, we performed metagenomics sequencing on viral capsid-protected nucleic acids from 12 primary and 8 metastatic human brain tumors. One brain tumor metastasized from a skin melanoma harbored two new human anellovirus species, Torque teno mini virus Emory1 (TTMV Emory1) and Emory2 (TTMV Emory2), while the remaining 19 samples did not reveal any exogenous viral sequences. Their genomes share 63-67% identity with other TTMVs, and phylogenetic clustering supports their classification within the Betatorquevirus genus. This is the first identification of betatorqueviruses in brain tumors. The viral DNA was in its expected non-integrated circular form, and it is unclear if the viruses contributed to tumor formation. Whether the viruses originated from blood, or the primary skin tumor could not be ascertained. Overall, our results demonstrate the usefulness of viral metagenomics to detect previously unknown exogenous virus in human brain tumors. They further suggest that active viral infections are rare events in brain tumors, but support a follow-up larger scale study to quantify their frequency in different brain tumor subtypes.Entities:
Keywords: anellovirus; brain tumor; metagenomics; metastasis; neuro-oncology
Year: 2017 PMID: 29285293 PMCID: PMC5739680 DOI: 10.18632/oncotarget.22400
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Schematic diagram outlines the typical viral metagenomic approach in this study, using filtration, nuclease and extraction (FNE) treatments [16, 17] to distinguish rare viral sequences from abundant host cell and free DNA
Black wavy lines denote host nucleic acids; blue wavy lines denote bacterial nucleic acids; red wavy lines denote viral nucleic acids. In the top panel, host (Left), bacteria (bottom), and viruses (right) are schematically represented. Viral nucleic acids are protected by viral capsids from degradation during nuclease (N) treatments, unlike the host and bacterial nucleic acids. Obtaining rare exogenous viral sequence through viral metagenomics (bottom panel left) is different from obtaining endogenous viral genomes through transcriptome or whole genome sequencing (bottom panel right).
Figure 2Comprehensive genomic and phylogenetic analysis of the Torque teno mini virus Emory1 (TTMV Emory1) and Torque teno mini virus Emory2 (TTMV Emory2)
(A) Schematic depiction of the TTMV Emory1 and Emory2 genome organization. Coverage for NGS data is indicated, and a portion of the representative NGS reads is shown. The circular genome is graphically linearized for display purpose, and the reads covering across the ends are marked with grey arrows on the extremities. (B) Pairwise whole genome nucleotide identities and ORF1 amino acid identities between Torque teno mini viruses. Protein sequences were aligned with MUSLE [52], and sequence identities were calculated using the species demarcation tool [53]. (C) ORF1 protein phylogeny of the genus Betatorquevirus, including the newly described TTMV Emory1 and Emory2. Maximum likelihood phylogeny was generated with PhyML [54], where branch support was calculated using Approximate Likelihood-Ratio Test (aLRT). The scale bar represents evolutionary distance in substitutions per site.
Figure 3PCR analysis of viral DNA
Arrows denote expected amplicon. TTMV Emory 1 PCR was performed with primers Emory1_AF and Emory1_AR with an amplicon size of 387 bp. TTMV Emory 2 PCR was performed with primers Emory2_AF and Emory2_AR with an amplicon size of 332 bp. M, size markers; #1-5, samples 1-5. Bands below the expected amplicon size were due to primers or primer dimers.
Human brain tumor specimens used for the study
| Sample number | Description | Age/sex | Weight |
|---|---|---|---|
| 1 | Metastasis, Carcinoma, primary of breast origin | 49/F | 233 mg |
| 2 | Metastasis, Carcinoma, poorly differentiated, primary of unknown origin | 67/M | 270 mg |
| 3 | Metastasis, Carcinoma, poorly differentiated, primary of unknown origin | 40/F | 351 mg |
| 4 | Metastasis, Adenocarcinoma with lung primary | 49/F | 291 mg |
| 5 | Metastasis, Melanoma, malignant, primary from skin | 57/M | 250 mg |
| 6 | Metastasis, Melanoma, malignant, primary from skin | 51/M | 244 mg |
| 7 | Metastasis, Adenocarcinoma, primary of breast origin | 38/F | 224 mg |
| 8 | Metastasis, Carcinoma, poorly differentiated, consistent with breast primary | 67/F | 244 mg |
| 9 | Schwannoma (I) | 32/F | 264 mg |
| 10 | Schwannoma (I) | 49/M | 223 mg |
| 11 | Medulloblastoma (IV) | 7/M | 231 mg |
| 12 | Medulloblastoma (IV) | 34/F | 213 mg |
| 13 | Pilocytic Astrocytoma (I) | 8/F | 237 mg |
| 14 | Anaplastic Astrocytoma (III), recurrence from pilocytic astrocytoma (I) | 76/M | 225 mg |
| 15 | Glioblastoma (IV), recurrence from oligodendroglioma (II) | 44/F | 251 mg |
| 16 | Glioblastoma (IV) | 55/M | 257 mg |
| 17 | Gliosarcoma (IV) | 59/M | 222 mg |
| 18 | Gliosarcoma (IV) | 83/F | 210 mg |
| 19 | Subependymoma (I) | 77/M | 263 mg |
| 20 | Subependymoma (I) | 59/M | 243 mg |
WHO 2006 classification grade is indicated for primary brain tumors. Weight of frozen sample used for analysis is indicated.